1. Home
  2. RWAY vs ZNTL Comparison

RWAY vs ZNTL Comparison

Compare RWAY & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Runway Growth Finance Corp.

RWAY

Runway Growth Finance Corp.

N/A

Current Price

$6.63

Market Cap

284.1M

Sector

N/A

ML Signal

N/A

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

N/A

Current Price

$2.61

Market Cap

289.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RWAY
ZNTL
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
284.1M
289.0M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
RWAY
ZNTL
Price
$6.63
$2.61
Analyst Decision
Buy
Buy
Analyst Count
8
10
Target Price
★ $8.04
$6.89
AVG Volume (30 Days)
277.2K
★ 1.0M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 20.39%
N/A
EPS Growth
N/A
★ 18.03
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.42
N/A
Revenue Next Year
$5.12
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$5.19
$1.21
52 Week High
$10.31
$6.95

Technical Indicators

Market Signals
Indicator
RWAY
ZNTL
Relative Strength Index (RSI) 51.42 29.45
Support Level $6.60 $2.09
Resistance Level $6.83 $4.06
Average True Range (ATR) 0.12 0.19
MACD -0.02 -0.02
Stochastic Oscillator 37.42 17.00

Price Performance

Historical Comparison
RWAY
ZNTL

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: